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Globular domain of the prion protein needs to be unlocked by
domain swapping to support prion protein conversion
Abstract
Prion diseases are fatal transmissible neurodegenerative diseases affecting many mammalian species.
The normal prion protein (PrP) converts into a pathological aggregated form, PrPSc, which is enriched
in the β-sheet structure. While the high resolution structure of the normal PrP was determined, the
structure of the converted form of PrP remains inaccessible to high resolution techniques. In order to
map the PrP conversion process we introduced disulfide bridges into different positions within the
globular domain of PrP, tethering selected secondary structure elements. The majority of tethered PrP
mutants exhibited increased thermodynamic stability, nevertheless they converted efficiently. Only the
disulfides which tether subdomain B1-H1-B2 to subdomain H2-H3 prevented PrP conversion in vitro
and in prion infected cell cultures. Reduction of disulfides recovered the ability of these mutants to
convert, demonstrating that the separation of subdomains is an essential step in conversion. Formation
of disulfide-linked proteinase K-resistant dimers in fibrils composed of a pair of single cysteine mutants
supports the model based on domain-swapped dimers as the building blocks of prion fibrils. In contrast
to previously proposed structural models of PrPSc suggesting conversion of large secondary structure
segments, we provide evidence for the conservation of secondary structure elements of the globular
domain upon PrP conversion. Previous studies already showed that dimerization is the rate-limiting step
in PrP conversion. We show that separation and swapping of subdomains of the globular domain is
necessary for conversion. Therefore, we propose that domain-swapped dimer of PrP precedes amyloid
formation and represents a potential target for therapeutic intervention.
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Prion diseases are fatal transmissible 
neurodegenerative diseases affecting many 
mammalian species. The normal prion protein 
(PrP) converts into a pathological aggregated 
form, PrPSc, which is enriched in the β-sheet 
structure. While the high resolution structure 
of the normal PrP was determined, the 
structure of the converted form of PrP remains 
inaccessible to high resolution techniques.  
In order to map the PrP conversion process we 
introduced disulfide bridges into different 
positions within the globular domain of PrP, 
tethering selected secondary structure 
elements. The majority of tethered PrP mutants 
exhibited increased thermodynamic stability, 
nevertheless they converted efficiently. Only the 
disulfides which tether subdomain B1-H1-B2 to 
subdomain H2-H3 prevented PrP conversion in 
vitro and in prion infected cell cultures. 
Reduction of disulfides recovered the ability of 
these mutants to convert, demonstrating that 
the separation of subdomains is an essential 
step in conversion. Formation of disulfide-
linked proteinase K-resistant dimers in fibrils 
composed of a pair of single cysteine mutants 
supports the model based on domain-swapped 
dimers as the building blocks of prion fibrils.  
In contrast to previously proposed structural 
models of PrPSc suggesting conversion of large 
secondary structure segments, we provide 
evidence for the conservation of secondary 
structure elements of the globular domain upon 
PrP conversion. Previous studies already 
showed that dimerization is the rate-limiting 
step in PrP conversion. We show that 
separation and swapping of subdomains of the 
globular domain is necessary for conversion. 
Therefore, we propose that domain-swapped 
dimer of PrP precedes amyloid formation and 
represents a potential target for therapeutic 
intervention. 
 
Prion diseases, also called transmissible 
spongiform encephalopathies, are 
neurodegenerative diseases affecting a variety of 
mammalian species from mink to cow, with 
human being no exception. In these diseases, 
cellular prion protein (PrPC) converts into the 
aggregated form PrPSc, which is the main 
component of the infectious agents, the prions (1). 
PrPC is a GPI-anchored protein found on the 
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 2 
membranes of neurons and many other cells (2). 
The N-terminal half of the protein, which is 
devoid of defined tertiary structure (3), is followed 
by a C-terminal globular domain composed of 
three α-helices (H1, H2, H3) and a short 
antiparallel β-sheet (composed of two strands, B1 
and B2) (Fig.1A) (4). High-resolution structures of 
the C-terminal domain of PrP from different 
species revealed the conservation of the protein 
fold (5). In contrast to the availability of structural 
information on PrPC, the characteristics of PrPSc 
make it inaccessible to high-resolution structure 
techniques (x-ray crystallography and high 
resolution NMR). PrPSc is characterized by 
increased content of β-secondary structure in 
comparison to PrPC (6-8). Epitope accessibility (9-
12), deuterium exchange (13-15), limited 
proteolysis and mass spectrometry (16) studies 
revealed differences in surface exposure between 
PrPSc and PrPC. Based on the electron microscopy 
of two-dimensional crystals of a truncated form of 
PrPSc, Wille et al. proposed a β-helix model of 
PrPSc (17). In this model, only the C-terminal part 
of H2 and H3 are conserved, while the majority of 
the remaining PrP forms a β-helix. A spiral model 
using molecular dynamics simulations was 
proposed based on the same experimental data 
predicting that all three helices are conserved, but 
that an additional β-strand is formed in the loop 
between B1 and H1 (18,19). In contrast to those 
two models, the major structural transformation 
was also predicted in the region of  B2, H2 and H3 
and connecting segments (13). This region was 
proposed to form a single-molecule extended layer 
(20). Several such layers stack on top of each other 
forming a parallel, in-register β-structure (20), 
which could also be supported by the solid-state 
NMR studies (21). Relevance of the in vitro 
conversion studies of the recombinant PrP was 
confirmed by the demonstration of infectivity of in 
vitro converted PrP (22-25). 
In order to map which PrP segments participate in 
the structural transition, we decided to design 
additional disulfide tethers into the globular 
domain of murine PrP (mPrP). Most of the PrP 
disulfide mutants were more stable than the wild-
type protein, however, the stability did not 
correlate with their conversion propensity. Our 
results reveal that disulfide tethering of the most of 
the secondary structure elements does not inhibit 
conversion, suggesting that the majority of the PrP 
secondary structure elements and their 
arrangement are conserved upon structural 
transition. Fibrillization results show that only 
covalent tethering of subdomain A (B1-H1-B2) to 
subdomain B (H2-H3) aborts fibrillization, 
demonstrating that separation of the two 
subdomains is a necessary step for the conversion. 
Our results are further supported by selective 
conversion of disulfide mutants in cell culture and 
by the fibrillization of mutants with two additional 
disulfide bonds. By engineering single cysteine 
mutants we show that a domain-swapped dimer is 
a building block of PrP fibrils.  
 
Experimental procedures 
 
Materials. 3F4 antibodies were purchased from 
Dako, Cy2-conjugated antimouse antibodies from 
Dianova, goat anti mouse HRP conjugated 
antibodies from Jackson ImmunoResearch,  and 
Ni-NTA resin from Qiagen. TEM grids were from 
SPI Supplies, mica from Ted Pella, AFM probes 
from NanoWorld, GdnHCl and urea were 
purchased from Fluka, cell culture media and  
chemicals were form Gibco (Invitrogen). All other 
chemicals were purchased from Sigma.  
 
Selection of possible sites for additional disulfide 
formation and molecular modeling. Most of the 
designed disulfide bridges were determined by 
analysis of structures of recombinant prion 
proteins, especially mPrP structure 1AG2 (26) 
using MODIP (Modeling of Disulfide bridges in 
Proteins) (27).  
The coordinates of two adjacent PrP molecules A 
and B, each derived from PDB entry 1XYX (28), 
were used to prepare the initial switched dimer 
model; the first switched dimer model D1 
consisted of coordinates of residues 121-162 from 
molecule A and 172-232 from molecule B, while 
the second switched dimer model D2 consisted of 
coordinates of residues 121-162 from molecule B 
and 172-232 from molecule A. The connecting 
residues 163-171 for each molecule D1 and D2 
were modeled using the program Modeler (29); 
different initial orientations and separations of the 
two adjacent PrP molecules A and B were 
used. Swapped dimers of PrP were docked using 
Gramm algorithm, based on smoothed potentials, 
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 3 
refinement stage, and knowledge-based scoring 
(30). 
 
Preparation of  PrP disulfide mutant constructs. 
For expression in E. coli, pairs of cysteines were 
introduced into the 3F4-tagged mPrP (L108M, 
V111M)  open reading frame (from residues 23 to 
230) cloned into plasmid pRSET A using the 
Quikchange kit. Pairs of cysteines corresponding 
to mutants CC7 and CC9 were also introduced into 
the 3F4-tagged mPrP open reading frame in 
pcDNA3.1 zeo (+) by site-directed mutagenesis 
and these open reading frames were further 
subcloned into the retroviral expression vector 
pSFF(31-33). The 3F4 tag was used to facilitate 
detection by 3F4 antibody and distinguish it from 
endogenous mPrP in infected cell lines. 
 
Protein expression, purification, and refolding. 
Plasmid pRSET A encoding mPrP mutants was 
transformed into competent E. coli BL21 (DE3) 
pLysS. The protein was purified from inclusion 
bodies and refolded on a Ni-NTA-column using a 
previously described protocol (34-36). The purity 
of mutant isolates was checked by SDS-PAGE. 
Disulfide formation was confirmed by mass 
spectrometry. 
 
Circular dichroism spectroscopy. Circular 
dichroism spectra were recorded on an Applied 
Photophysics Chirascan spectropolarimeter. Far-
UV CD spectra were recorded between 190 and 
250 nm in a 1 mm path length cuvette at a protein 
concentration of 0.1 mg/ml. The thermal stability 
of proteins was recorded in a 1 mm path length 
cuvette at protein concentrations of 0.1 mg/ml 
with a temperature scan rate of 1 ºC/ min at 222 
nm.  
 
Conversion to the fibrillar form of the prion 
protein. A conversion reaction adopted from 
Bocharova et al. (37) was used for tracking the 
fibrillization of PrP disulfide mutants. Correctly 
folded proteins were first denatured in 6 M 
GdnHCl. The amyloid forms were produced by 
diluting denatured WT and mutants into 1 M 
GdnHCl, 3 M urea, phosphate buffered saline pH 
6.8 at protein concentrations of 22 μM and shaking 
at 37 °C (37).   
 
Thioflavin T fluorescence. A Perkin Elmer LS55 
fluorimeter was used for fluorescence 
measurements. ThT emission (460-535 nm) was 
tracked by excitation at 442 nm at a protein 
concentration of 1 μM and 5 μM ThT. 
 
Transmission electron microscopy. After 
conversion the reaction mixtures were adsorbed to 
poly-L-lysine coated holey formvar carbon-coated 
copper grids for 3 min, negatively stained with 1 
% (w/v) aqueous uranyl acetate for 1.5 min, and 
observed under a Jeol 100CX electron microscope 
operating at 80 keV as previously described (35). 
 
Atomic force microscopy. A drop of PrP (0.22 µM) 
was appiled to freshly cleaved mica and left to 
adsorb for 5 min after which it was washed twice 
with filtered Milli-Q water and dried under the 
stream of nitrogen. Samples were observed by 
Agilent Technologies 5500 Scanning Probe 
Microscope operating in acoustic alternating 
current mode utilizing silicon cantilevers 
(Arrow-NCR) with force constant 42 N/m.  
 
Indirect ELISA using POM antibodies.Wild-type 
PrP and PrP disulfide mutants in native and 
amyloid form were coated into maxisorp 
microtiter plates (Nunc) at various concentrations. 
After protein adsorption, wells were blocked by 1 
% BSA. Anti-PrP antibodies of the POM panel 
(38) POM1 (7.5 ng/ml), POM2 (4.8 ng/ml), POM3 
(15 ng/ml), POM4 (10 ng/ml) and POM5 (15 
ng/ml) were added. After washing, goat anti 
mouse HRP conjugated antibodies were added and 
absorbance (at 405 nm) was detected after the 
addition of substrate ABTS.  
 
Conversion and analysis of single cysteine mutants 
M133C and Q216C. Fibrillization was initiated by 
diluting WT and single cysteine mutants into 1 M 
GdnHCl, 3 M urea, phosphate buffered saline pH 
6.8 at total protein concentrations of 22 μM and 
shaking at 37 °C. The molar ratio of M133C and 
Q216C was 1:1 (11 μM of each mutant). 
Fibrillization reactions were diluted with 0.1 M 
Tris buffer pH 7.5 and subjected to different 
proteinase K: PrP ratios for 45 min at 37°C. The 
digestion was stopped with 5 mM PMSF. Proteins 
were precipitated by methanol and solubilized in 
denaturing sample buffer without or with β-
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 4 
mercaptoethanol (39). Detection of prion protein 
specific bands was achieved by POM1 antibody 
(1:4000). 
 
Production of retrovirions and transduction of 
HpL3-4 and L929/22L cell lines. The pSFF vectors 
were transfected into co-culture of packaging cell 
lines ψ2 and PA317. When cells were more than 
80% positive for prion protein, retroviral 
supernatants were harvested and cleared by 
centrifugation (120 g, 4 °C, 10 min). 3 x 105 cells 
per well of HpL3-4 (40) or L929 cells persistently 
infected with prion strain 22L (41) were plated a 
day before transduction into 6-well plates. Cells 
were incubated with polybrene (4 µg/ml) 2 h 
before addition of retrovirions. 1 mL of retroviral 
supernatant was incubated with the cells for 2 
days, after which the cells were transferred into a 6 
or 10 cm culture plate.  
 
Flow cytometry. We used a flow cytometry 
protocol adapted from Maas et al. to check 
whether PrP disulfide mutants are expressed at the 
cell surface of HpL3-4 cells similarly to the wild-
type PrP (42). 5 x 105 cells were first incubated 
with FACS buffer (2.5 % FCS in PBS) for 10 min 
at 4 °C. 100 µl of 3F4 antibody (5 μg/ ml) was 
added to the cells and incubated for 45 min at 4 
°C. After washing, the cells were incubated with 
Cy2-conjugated anti-mouse secondary antibodies 
for 45 min at 4 °C in the dark. The rinsed cells 
were analyzed by flow cytometry. 
 
Infection of HpL3-4. A day before infection 5 x 
104 cells were seeded into each well of a 24-well 
microtiter plate. 200 µL of DMEM supplemented 
with 10% serum and 1% 22L-positive brain 
homogenate were added to the cells and incubated 
for 4 h. After this incubation 400 µL of growth 
medium were added and the cells were left to grew 
to near confluence when the cells were moved 
stepwise into 6 cm and 9 cm Petri dishes (41,42).  
 
Analysis of protease-resistant PrP. Infected Hpl3-
4 and transduced L929/22L cells were washed and 
lysed. 1/10 of the sample was methanol 
precipitated and used for determination of the total 
amount of PrP. The rest of the sample was 
incubated with proteinase K (20 µg/ml) at 37°C 
for 30 min when the proteinase digestion was 
stopped by the additon of Pefabloc and 
ultracentrifuged. Pellets were resuspended in SDS-
sample buffer and analyzed by Western blot. A 
3F4 antibody was used for the detection of the 
conversion of mutant proteins (transduced 3F4-
tagged wild-type mPrP, CC7 and CC9) and a 
4H11 antibody (43) was used for the detection of 
endogenous and mutant proteins. 
 
RESULTS 
 
Engineering of additional disulfides into the mPrP 
structure. In order to map the PrPC to PrPSc 
conversion we designed nine additional disulfide 
bridges into the globular domain of mouse PrP 
(Fig. 1B). All sites matched steric criteria favoring 
disulfide formation (27) and were chosen to tether 
different secondary structure elements of the 
globular domain of mPrP. PrP disulfide mutants 
CC1, CC3 and CC5 had disulfides introduced 
within the B1-H1-B2 segment, with CC1 
enclosing the longest and CC5 enclosing the 
shortest segment (Fig. 1B). The H2-H3 region, 
which is already connected by a native disulfide 
was also tethered by additional disulfides in CC8 
and CC9 mutants. Disulfides tethering the longest 
polypeptide segment belonged to CC2 and CC4, 
where the B1-H1-B2 region was tethered to H3, 
and CC7 connecting B2 to H3. We were able to 
purify and refold seven PrP disulfide mutants (Fig. 
S1). As the wild-type PrP (WT), all refolded 
mutants had a high content of α-helical structure, 
characterized by two minima in the far-UV CD 
spectrum (Fig. S2A). We were unable to refold 
mutants CC6 and CC8, probably due to the 
proximity of the native and engineered cysteines. 
While the majority of additional disulfides 
increased protein stability (Table 1, Figure S2B), 
only the CC5 disulfide placed at the N-terminus of 
H1 destabilized the mutant compared to WT by 
approximately 6°C. Mutants CC2 and CC3, one 
enclosing 82 and the other enclosing 19 amino 
acid residues were the most stable mutants in our 
panel of PrP disulfide mutants. Determination of 
disulfide mutant stability suggests that local 
packing interactions affect stability rather than the 
length of the loop enclosed by the additional 
disulfide. 
 
Fibrillization of PrP disulfide mutants. In vitro 
fibrillization enables to monitor the time course of 
PrP conversion by fluorescence emission of 
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 5 
amyloid-specific dye thioflavin T (37) (Fig. 2A). 
Conversion of the WT and CC5 mutant was 
detected after 12 h, followed by CC9 and CC3. 
The fibrillization delay of CC1 mutant was 
considerably longer. In contrast, the CC2, CC4 
and CC7 mutants did not fibrillize even after as 
much as one month (Fig. 2A). The converted 
mutants showed a structural transition to a 
conformation with increased content of β-
secondary structure, which was confirmed by CD 
(not shown). Fibrils of morphology similar to WT 
were confirmed by TEM (Fig. S3). No fibrils were 
detected in samples of CC2, CC4 and CC7 (Fig. 
3C left). CC5, which is less stable than WT, 
fibrillizes with comparable kinetics to WT. 
Mutants CC2, CC4 and CC7, which are more 
stable than WT, do not convert at all. However, 
mutant CC3 with the highest Tm converts only 
with slightly longer delay than WT. Those results 
show that thermal stability has less influence on 
conversion propensity than the structural context 
of each mutant. 
To further characterize fibrils of different PrP 
disulfide mutants, we used a panel of 5 antibodies 
with well-characterized epitopes on mouse PrPC 
(38,44). We tested recognition of PrP disulfide 
mutants in the native and fibrillar form. The 
POM2 antibody with a recognition epitope in the 
octarepeat region bound to both forms of all 
mutants (Fig. 2B), demonstrating that octarepeat 
region is not buried in fibrils. In contrast to the 
octarepeat-binding antibody POM2, other 
antibodies did not bind to the fibrillar form of 
mPrPs while they bound well to the native α-
helical form (Fig. 2C, Fig. S4A-C). All antibodies 
recognized CC2, CC4 and CC7 mutants under 
native conditions as well as under fibrillization 
conditions since these mutants did not convert into 
fibrils but retained the α-helical structure (Fig. 2C, 
Fig. S4A-C).  
 
Reduction of disulfide bonds reverts conversion 
ability to PrP disulfide mutants. Since even single 
amino acid substitutions may inhibit PrP 
conversion (45), we wanted to exclude the 
possibility that the amino acid substitutions 
introduced for the engineered disulfide affected 
the conversion process. Therefore, we prepared 
single cysteine mutants corresponding to point 
substitutions for the construction of CC2 disulfide 
mutant. Each of the single cysteine mutants 
fibrillized comparably to WT (Fig. 3A). To prove 
that the covalent tethers restrict conversion, we 
exposed non-converting mutants CC2, CC4 and 
CC7 and WT to reducing conditions prior to 
fibrillization in order to disrupt disulfide bonds. 
This reverted the effect of disulfide tethers in non-
converting mutants and all mutants fibrillized with 
a delay comparable to the wild-type protein (Fig. 
3B, 3C). These results show that the restriction of 
the conformational space by disulfide tethers and 
not an amino acid substitution per se is the reason 
for non-conversion of the selected group of PrP 
disulfide mutants. 
 
PrP conversion in cell culture confirms selective 
inhibition of in vitro fibrillization. We wanted to 
test whether PrP disulfide mutants have the same 
conversion propensities in the living cells. We 
expressed the representatives of non-converting 
(CC7) and converting (CC9) mutants and WT 
mPrP by retroviral transduction into prion protein 
knock-out cell line HpL3-4 (40,42). Both mutants 
as well as wild type PrP were expressed at the 
comparable amount at the cell surface (Fig. S5A). 
HpL3-4 cells expressing CC7, CC9 and WT 
protein were exposed to prion strain 22L. While 
wild-type mPrP and CC9 supported prion 
propagation, as detected by the occurrence of 
proteinase K-resistant PrPSc (Fig. S5B right), CC7 
did not convert into the protease-resistant form, 
which is in agreement with the results of in vitro 
assay.  Additionally we were interested whether a 
non-converting mutant CC7 has a dominant 
negative phenotype on the propagation of 
endogenous PrPSc. To test this we introduced WT, 
CC7 and CC9 mutants into cell line L929 
chronically infected by prion strain 22L. All three 
mutants were expressed in L929 cell line (Fig. 
S5C left). As in the HpL3-4 cell line, the CC9 
mutant converted into protease resistant PrP, while 
the CC7 mutant did not (Fig. S5C middle). The 
expression of CC7 did not affect the amount of 
endogenous PK-resistant PrP (Fig. S5C right), 
from which we can conclude that CC7 does not 
inhibit PrP conversion.  
 
Fibrillization of mutants with two engineered 
disulfide bridges from different subdomains of 
mPrP. We can divide the C-terminal globular 
domain of PrP into subdomain A, consisting of 
secondary structure elements B1-H1-B2 and 
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 6 
subdomain B, consisting of helices H2 and H3 
(Fig. 4A). Converting mutants CC1, CC3 and CC5 
have an additional disulfide bond in the 
subdomain A and mutant CC9 in the subdomain 
B. In the non-converting mutants, on the other 
hand, either the loop between B1 and H1 is 
connected to H3 (CC2 and CC4) or B2 is tethered 
to H3 (CC7), thereby tethering the two 
subdomains together.  
It might be possible that disulfide tether in one 
segment could be compensated by the 
conformational adaptation in the other subdomain. 
To further investigate the conservation of the 
secondary structure elements within the 
subdomains, we produced mutants with two 
engineered disulfide bridges, one in each 
subdomain. Mutant CC3&9 contains a disulfide 
bridge of CC3 in subdomain A and in subdomain 
B a disulfide corresponding to CC9. Mutant 
CC5&9 is tethered by a combination of CC5 
disulfide in subdomain A and CC9 disulfide in 
subdomain B. Both mutants were correctly 
refolded and even though they were significantly 
more stable than the wild-type protein (CC5&9 
had a melting temperature of 67.7 ± 0.2 °C and 
CC3&9 of more than 80°C), they were 
nevertheless able to convert (Fig. 4B, 4C).  
We can conclude that a tether between 
subdomains A (B1-H1-B2) and B (H2-H3) 
prevents the conformational change, while intra-
subdomain disulfide bridges allow conversion. 
This suggests that the conformation of each 
subdomain is conserved in the PrPSc, but that 
separation of subdomains A and B is necessary for 
the conversion to proceed with the loop between 
B2 and H2 as the pivot of conformational 
transition to amyloid form (Fig. 4A). 
 
Domain swapping is the mechanism of PrP 
conversion. Our results showing that only 
separation of subdomains without disruption of the 
existing secondary structure elements is necessary 
for conversion led us to propose that domain 
swapping is involved in the PrP conformational 
transition. To test this hypothesis we employed a 
pair of single cysteine mutants corresponding to 
CC2. Similar approach has been used previously 
to show that domain swapping is envolved in 
fibrillization of T7 endonuclease I (46). We 
expected that when the mixture of M133C and 
Q216C undergoes fibrillization, monomers form 
swapped dimers with either monomers of the same 
mutant or monomers of the other mutant. In the 
latter case a disulfide bond is formed between 
monomers only if domain swapping occurs (Fig. 
5A). We fibrillized M133C, Q216C and a mixture 
of both mutants (Fig. 5B right). When fibrils were 
exposed to increasing concentrations of proteinase 
K, proteinase K resistant dimers were observed in 
fibrils composed of both mutants (Fig. 5B left). 
Reduction of these dimers yielded monomers, 
showing these dimers are covalently bound by a 
disulfide bridge (Fig. S6). No proteinase K-
resistant dimers were observed in fibrils of 
separate single cysteine mutants (Fig. 5B left) or 
in wild-type mPrP (Fig. S7), which however 
display similar characteristics regarding fibril 
formation and aggregation upon PK-digestion as 
previously reported (37) (Fig. S8). When single 
cysteine mutants are exposed to mildly denaturing 
conditions, they are partially unfolded and a 
fraction of molecules forms covalent dimers, 
which however do not incorporate into fibrils and 
are thus degraded by proteinase K (Fig. 5B left, 
Fig. S9).  
In the molecular model of PrP conversion 
satisfying our disulfide constraints, subdomains A 
and B dissociate and interact with the 
corresponding subdomains of the other monomer 
thus forming a domain-swapped dimer (Fig. 5C). 
Since the secondary structure elements of both of 
the subdomains are conserved, most of the helical 
segments remain. However, the β-sheet content 
increase can arise from the conversion of the B2-
H2 loop into the extended structure and 
particularly from ordering of the unstructured N-
terminal hydrophobic region.  
 
DISCUSSION 
The major unsolved question regarding prion 
diseases is the transformation of tertiary structure 
of PrP, where the converted form (PrPSc) 
comprises the major component of the infectious 
particle. Results of our study reveal that a 
significant amount of the native-like 
supersecondary structure is retained in the fibrillar 
form of PrP, since disulfide tethers introduce very 
strong structural constraints that are incompatible 
with the major structural transformation of its 
secondary structure elements. Other published 
PrPSc models predict significant rearrangement of 
secondary structure elements in the globular 
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domain. The β-helix model (17) and the spiral 
model (19) agree with our results in the 
conservation of the major part of H2 and H3. 
However, the β-helix model (17) proposes that 
residues up to the middle of H2 change the 
conformation, which is incompatible with the 
ability of mutants CC1, CC3, CC5 to convert. The 
spiral model (19) proposes an additional β-strand 
formation in the segment connecting B1 and H1, 
which would be expected to prevent conversion of 
mutant CC3. The models predicting major 
structural changes in the subdomain B (20) are 
also not supported by our results (conversion of 
mutant CC9) and additionally by the presence of 
the native disulfide bridge. The three non-
converting disulfide mutants show that in the 
structural conversion of PrP subdomains A and B 
have to dissociate, which is also supported by a 
study by Eghiaian et al. showing that connecting 
residues 160 and 209 in ovine PrP disabled 
oligomer formation (14).  
Our molecular model of PrPSc contains 34% α-
helices and 39% β-sheets, which is close to the 
experimentally determined secondary structure 
content (6-8,47). According to this model, the 
main structural switch is located in the loop 
between B2 and H2. This region has been 
previously implicated in the species barrier (48) 
and disease resistance polymorphisms (49). NMR 
investigation identified differences in structural 
order parameter in this region, with PrP from elk 
being more rigid than in other species, therefore it 
was called “the rigid loop” (28). Additionally, 
substitutions in rigid loop led to spontaneous 
transmissible prion disease in transgenic mice 
(50).  
Dimerization has been pinpointed as the rate 
limiting step in PrP conversion (51) and the 
electron microscopy of PrP fibrils supports the 
dimer as the building unit of fibrils (52). A model 
of PrP dimer which involves ordering of the region 
90-124 is also in agreement with our results 
(53,54). Domain swapping mechanism as the 
underlying motif of  fibrillization has already been 
proposed for several amyloid-like proteins (55-
57). Our non-converting mutant (CC7) failed to 
cure chronically infected cells, which can be 
explained by the inability of the mutant to 
sequester the wild-type mPrP into the domain-
swapped dimer. Interestingly, a crystal structure of 
domain-swapped PrP dimer was determined 
(58,59), where H3 was involved in domain-
swapping. This type of crystallized dimer, 
however, requires disruption of the native 
disulfide bond, whereas previous studies have 
shown that the native disulfide bond is conserved 
upon conversion (60,61). There is emerging 
evidence that polyanions such as nucleic acids and 
glucosaminoglycans can modulate PrP conversion 
(62-65). It is proposed they may act as a scaffold 
facilitating protein-protein interactions (64), which 
should augment domain-swapped dimer 
formation. On the other hand molecules such as 
heparin are effective inhibitors of PrPSc conversion 
(65). By binding to the globular domain (66) 
heparin could stabilize PrP monomer thus 
inhibiting dimer formation.    
Recently several  prion strains were produced in 
vitro, differing primarily in fibril morphology 
(67,68) and also in incubation periods in 
inoculated mice (68).  By epitope accessibility 
studies using a panel of antibodies we showed that 
the fibrils of mutants with engineered disulfides 
are indistinguishable from WT fibrils. Those 
experiments, however, allow the possibility of 
different stacking of N-terminal part preceding the 
globular domain. This part is not tethered by our 
disulfides and has been shown to differ in 
conformational stability among prion strains (69). 
Increase of the β-structure in PrPSc has been 
generally attributed to the conversion of α-helical 
segments into the β-sheet structure and different 
conformations of PrP were proposed to account 
for prion strains. However, several radically 
different secondary structure conformations of the 
same polypeptide chain are very unlikely to exist, 
as they would have to satisfy large number of 
structural constraints simultaneously. On the 
contrary, it is much more likely to fold the 
disordered N-terminal polypeptide chain of PrP 
into several different β-sheet arrangements. 
Recently Wiltzius et al. (70) demonstrated that the 
same short peptide sequence can pack into 
different polymorphic β-sheets, which has been 
proposed as the background of protein-encoded 
inheritance. Using additional disulfide bonds as 
tethers we were able to show that dissociation of 
the two subdomains, which enables swapped 
dimer formation, is the necessary step in the PrP 
structural conversion. The main role of the 
globular C-terminal domain in the prion protein 
encoded inheritance is to act as a switch that 
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allows the annealing of the β-structure from the 
disordered N-terminal polypeptide segments. 
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FIGURE LEGENDS 
 
Fig. 1. Scheme of sites for additional disulfide formation. 
(A) Mouse prion protein is composed of a N-terminal unfolded part (gray line) and a globular domain, 
which consists of α-helices H1, H2 and H3 and an antiparallel β-sheet (B1 and B2) (1XYX (28)). Dashed 
line in the unfolded N-terminal part represents octarepeat region. (B) Below the representation of 
secondary structure elements dotted lines connect the positions of engineered disulfides in PrP disulfide 
mutants. The native disulfide bridge connects amino acid residues 178 and 213 and is drawn as a solid 
line. Mouse PrP numbering is used. 
 
Fig. 2. In vitro conversion of PrP disulfide mutants. 
(A) Fluorescence emission of amyloid specific dye thioflavin T (ThT) at 482 nm was used to follow the 
time course of the conversion of PrP disulfide mutants CC1 (), CC2 (), CC3 (), CC4 (), CC5(), 
CC7(), CC9 () and WT () in vitro. A representative of four experiments is shown. (B) Binding of 
mAb POM2 recognizing the epitope in the octarepeat region in the N-terminal unstructured part to PrP to 
the native (α-form, left part of the chart) or fibrils (right part of the chart). Proteins were applied to 
microtiter plates at protein concentrations 0.5 µg/ml ( ), 1 µg/ml ( ) 2 µg/ml ( ), 3 µg/ml ( ) and 5 
µg/ml ( ). In the case of non-converting mutants CC2, CC4 and CC7 the conversion reaction mixture 
was used (designated by *). (C) Binding of mAb POM5 to the α-form and fibrils of WT and mutants. 
POM5 binds to the region between B2 and H2 in the globular domain. POM5 does not bind to CC1 in any 
form since the substitution Y161C lies in the recognition epitope of POM5. 
 
Fig. 3. Recovery of conversion of PrP disulfide mutants under the reducing conditions and 
conversion of single cysteine mutants. 
(A) Fibrillization of WT () and single cysteine mutants of the pair of cysteines of mutant CC2: M133C 
() and Q216C (). A representative of three experiments is shown. (B) Conversion of WT () and 
non-converting mutants CC2 (), CC4 () and CC7 () in vitro in the presence of reducing agent (5 
mM DTT). A representative of three experiments is shown. (C) Formation of fibrils was confirmed by 
transmission electron microscopy. No fibrils were observed in samples of CC2, CC4 and CC7 without the 
reducing agent (left), addition of the reducing agent to the conversion reaction resulted in fibrils observed 
under TEM (right).  
 
Fig. 4. Dissociation of subdomains in the globular domain is necessary for conversion, but is not 
inhibited by two additional disulfide bridges in separate subdomains of PrP . 
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(A) Disulfide tethers reveal the importance of the dissociation of subdomains A (yellow) and B (blue) in 
the conversion process. (B) Conversion of mutants with two additional disulfide bridges CC5&9 () and 
CC3&9 () with one disulfide bridge in subdomain A and the other in subdomain B was followed by 
ThT emission. (C) Fibrillization of double disulfide mutants was confirmed by TEM. 
 
Fig. 5.  Domain-swapped dimers are the building blocks of PrP fibrils.  
(A) Shematic representation of the fibrillization experiment using a mixture of two single cysteine 
mutants. These cysteines could form a disulfide, if they were within the same protein monomer. When 
one cysteine mutant monomer (yellow) forms a domain-swapped dimer with the other cysteine mutant 
monomer (blue), a covalent disulfide-linked dimer can be formed (disulfide bridge is depicted as a cyan 
star). Each mutant monomer can also swap H2-H3 subdomain with the monomer of the same mutant, 
which however, can not lead to the formation of disulfide bridge. Cysteines are depicted by red spots. 
After proteinase K digestion, the N-terminal part of the protein is partially cleaved off the fibrils. 
(B) Fibrillization reactions of the mixture of M133C with Q216C and each of the mutants separately were 
exposed to proteinase K (PK) at PK: PrP ratios (w/w) 1:650, 1:160 and 1:80. The first lane in each case is 
fibrillization reaction not treated with PK. Only in the case of mixture of M133C and Q216C, a proteinase 
K resistant dimer is observed (bands between monomer (M) and dimer (D)). TEM images of fibrils 
formed by the mixture of M133C with Q216C and by each mutant separately are shown on right. Bar 
represents 250 nm. 
(C) Model of stacking of domain-swapped dimer units into a fibril (right). Dimer is formed by domain-
swapping of PrP, where the H2-H3 subdomain of one monomeric unit interacts with the B1-H1-B2 
subdomain of the other monomeric unit (left). Each monomer of the domain swapped dimer is 
represented by a different color (yellow, blue). β-strands annealed to the swapped dimers form from the 
disordered N-terminal segments and connect the dimer units (right). 
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Table 1. Thermal stability of PrP disulfide mutants. 
Thermal stability of PrP mutants was determined from circular dichroism at 222 nm. The engineered 
disulfide bridge increases stability of the majority of PrP disulfide mutants in comparison to WT. For the 
most stable mutants only the lower limit is indicated, as the Tm could not be calculated accurately. 
 
 
 
 
Protein No. of amino acid 
residues enclosed 
Tm (°C) 
wt - 63.5 ± 0.2 
CC1 35 66.6 ± 0.1 
CC2 84 > 75 
CC3 19 > 76 
CC4 76 > 72 
CC5 5 57.9 ± 0.2 
CC7 53 69.7 ± 0.4 
CC9 6 70.5 ± 0.1 
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Figure 1 
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Figure 2  
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Figure 3  
 
 
A                                                                             B 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
C 
 
 
 
 
 
 
 at H
auptbibliothek Universitaet Zuerich Irchel. Bereich Forschung, on M
arch 31, 2011
w
w
w
.jbc.org
D
ow
nloaded from
 
 17 
0 2 4 6 8
0
100
200
300
400
500
600
Fl
uo
re
sc
en
ce
 in
te
ns
ity
t (d)
CC5&9 CC3&9 
CC3&9           
250 nm 
CC5&9 
Figure 4 
 
A 
 
      
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B        C 
 
                                                                  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B1 
B2 
H1 
H2 
H3 
H1 
B1 
B2 
H2 
H3 
subdomain 
separation 
 at H
auptbibliothek Universitaet Zuerich Irchel. Bereich Forschung, on M
arch 31, 2011
w
w
w
.jbc.org
D
ow
nloaded from
 
 18 
Figure 5 
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